Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Overview of attention for article published in Frontiers in immunology, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 4 news outlets

twitter: 15 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 34 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 4 news stories from 4 outlets.

Caring for a Patient Undergoing CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Oncology Nursing News, 22 Dec 2023

Nicole McEntee, BSN, RN, OCN, BMTCN The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple…

ASH 2023: Advances in Combination Therapy for Newly Diagnosed Multiple Myeloma

Cancer Therapy Advisor, 19 Dec 2023

By Clinical Content Hub James R. Berenson, MDInstitute for Myeloma and Bone Cancer Research, West Hollywood, California Key…

BCMA靶点开发进度如何？哪种biotech将胜出？

CN-Healthcare, 26 Jul 2022

从上市情况来看，Belantamab mafodotin (GSK2857916) 由人源化靶向BCMA IgG1 和MMAF（微管蛋白聚合抑制剂）组成，这是第一款获准上市的靶向BCMA免疫疗法。前言恶性多发性骨髓瘤(multiple myeloma …

What to know about BCMA-targeted treatment for multiple myeloma

Medical News Today, 30 Jun 2022

B cell maturation antigen (BCMA) targeted immunotherapy can treat multiple myeloma.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.